y*****l
发帖数: 5997 | | q********g
发帖数: 10694 | 2 好~~顶
手里捂着AVII均价1.85。NBS看起来挺适合我的风格的。 | f**********g
发帖数: 2252 | 3 NBS CUR chart looks good, but do not know their drugs.
【在 q********g 的大作中提到】
: 好~~顶
: 手里捂着AVII均价1.85。NBS看起来挺适合我的风格的。
| f**********g
发帖数: 2252 | | q********g
发帖数: 10694 | 5 这个太猛了~~
【在 f**********g 的大作中提到】
: PSTI continue up.
| i****s
发帖数: 1152 | 6 这avii看的我胆战心惊的。今天一大叉，在加上KDJ和RSI都说是超买了....
本来还指望3呢.... | f**********g
发帖数: 2252 | 7 ASTM continue after pullback.
PSTI continue up.
AVII pullback. | f**********g
发帖数: 2252 | 8 Anyone familiar with NBS?
http://finviz.com/screener.ashx?v=341&t=NBS
NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday
, January 12, 2011
1 hours 20 minutes ago - PRN
PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
international biopharmaceutical company with operations in the U.S. and
China, today announced that Dr. Robin Smith, the Company's Chairman and CEO,
will present on Wednesday, January 12, 2011 at the OneMedForum 2011 at 9:15
AM PST and at the Biotech Showcase(TM) 2011 at 11:00 AM PST. Both events
will be held in San Francisco, California.
The OneMedForum 2011 will be held at the Sir Francis Drake Hotel at 450
Powell Street, San Francisco, CA and Dr. Robin Smith will present in the
Renaissance Room. The Biotech Showcase(TM) 2011 will be held at Parc 55
Wyndham San Francisco, CA and Dr. Robin Smith will present in the Stockton
Room.
In recapping highlights of 2010, the Company will review its multiple
accomplishments for the year. In November 2010, we raised $19 million from
two concurrent offerings. These funds will help us to grow our revenue lines
of businesses in the US and China, including the closing of our acquisition
of Progenitor Cell Therapy LLC, and further assist in our growth. NeoStem
was also named "Best Stem Cell Company, 2010" in The New Economy's Biotech
Awards. Additionally, The Vatican's Pontifical Council has undertaken to
commit $1 million to joint ventures with NeoStem and the Stem for Life
Foundation, a not-for-profit entity NeoStem participated in founding, to
expand research and raise awareness of adult stem cell therapies.
We also began generating revenues from what we believe will be just the
beginning of a pipeline of stem cell-based regenerative medicine therapies,
a key element of our growth strategy in both the United States and China,
with our collaboration with Wendeng Hospital in China whereby patients are
being offered the benefit of the latest technology from the US in the
treatment of a range of orthopedic conditions. Additionally, the ongoing
relocation to Suzhou Erye Pharmaceutical's new manufacturing facility
continues to progress and should be completed in 2011 thereby significantly
increasing capacity.
"I look forward to the opportunity to detail some of these exciting
developments as well as discuss some of our upcoming milestones at these two
industry events in San Francisco," said Dr. Robin Smith.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies,
pursuit of anti-aging initiatives and building of a network of adult stem
cell collection centers in the U.S. and China that are focused on enabling
people to donate and store their own (autologous) stem cells for their
personal use in times of future medical need. The Company also has licensed
various stem cell technologies, including a worldwide exclusive license to
VSEL(TM) Technology which uses very small embryonic-like stem cells, shown
to have several physical characteristics that are generally found in
embryonic stem cells, and is pursuing the licensing of other technologies
for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical
operation, Suzhou Erye, manufactures and distributes generic antibiotics in
China. For more information, please visit: http://www.neostem.com.
About the Biotech Showcase(TM) (Innovation - Opportunity - Collaboration)
Now in its third year, Biotech Showcase(TM) will feature corporate
presentations by 195 innovative life science companies to an audience of
public and private investors, business development executives and
professional advisors who are interested in investment opportunities and
collaboration. The showcase takes place during the week of one of the most
important healthcare investor conferences which annually attracts thousands
of healthcare and life science business executives to San Francisco in a
venue located close to the center of action. More can be found on their
website: http://www.ebdgroup.com/bts/index.php.
【在 f**********g 的大作中提到】
: NBS CUR chart looks good, but do not know their drugs.
| f**********g
发帖数: 2252 | 9 $1,700,000 Funding of NeoStem's Very Small Embryonic-Like Stem Cells Being
Developed to Treat Osteoporosis Recommended by the Department of Defense
Peer Reviewed Medical Research Program
41 minutes ago - PRN
PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
international biopharmaceutical company with operations in the U.S. and
China, today announced that its FY2010 Technology/Therapeutic Development
Award application number PR101055 has been recommended for funding by the
Department of Defense (DOD) Peer Reviewed Medical Research Program (PRMRP)
of the Office of the Congressionally Directed Medical Research Programs (
CDMRP).
The $1,700,000 award, which the Company will receive upon completion of the
award process, will be applied towards funding the Company's proposal to
continue a strategy aimed at employing the Company's VSEL(TM) Technology
which uses a unique stem cell population, very small embryonic-like stem
cells, to treat osteoporosis and improve bone health.
"The work proposed in this application has the potential to dramatically
change the way in which osteoporosis and bone fracture is treated in the
military and in the general population," said Dr. Russell Taichman,
Professor of Dentistry, Department of Periodontics and Oral Medicine at the
University of Michigan's School of Dentistry who will work with the Company
on the study. Dr. Taichman added "Osteoporosis is a major medical condition
affecting 75 million people worldwide and causing significant morbidity and
mortality in the aging population and the increased incidence of fractures
is the major cause of death from osteoporosis. In 2005, the estimated cost
burden of fractures due to osteoporosis was $19 billion and that is expected
to rise to over $25 billion by the year 2025. In addition to being a major
concern for the general healthcare community, osteoporosis and related bone
fractures have become a concern for the military with significant loss of
duty time across all branches of the military due to related stress
fractures."
Dr. Denis Rodgerson, NeoStem's Director of Stem Cell Science and Principal
Investigator for the study commented, "We are honored to have been
recommended for this award. It will enable us, together with Dr. Taichman as
co-Principal Investigator and his colleague Dr. Laurie K. McCauley, Chair,
Department of Periodontics and Oral Medicine at the University of Michigan's
School of Dentistry and Professor of Pathology at the University of
Michigan Medical School, to explore the significant potential for VSEL(TM)
Technology to provide benefits in autologous, cell-based therapies for
osteoporosis and other diseases of the bone."
Dr. Robin Smith, NeoStem's CEO commented, "We are thrilled that such a
preeminent authority as the Department of Defense shares our excitement and
vision regarding the clinical applications of our licensed technologies and
continues to support the advancement of our VSEL(TM) Technology in multiple
clinical applications."
NeoStem has a worldwide exclusive license to VSEL(TM) Technology which uses
very small embryonic-like stem cells, a heterogeneous population of stem
cells found in adult bone marrow that have properties similar to those of
embryonic stem cells. NeoStem has shown that very small embryonic-like stem
cells can be mobilized into the peripheral blood, enabling a minimally
invasive means for collecting what NeoStem believes to be an important
population of stem cells that may have the potential to achieve the positive
benefits associated with embryonic stem cells without the ethical or moral
dilemmas or the potential negative effects associated with embryonic stem
cells.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies,
pursuit of anti-aging initiatives and building of a network of adult stem
cell collection centers in the U.S. and China that are focused on enabling
people to donate and store their own (autologous) stem cells for their
personal use in times of future medical need. The Company also has licensed
various stem cell technologies, including a worldwide exclusive license to
VSEL(TM) Technology which uses very small embryonic-like stem cells, shown
to have several physical characteristics that are generally found in
embryonic stem cells, and is pursuing the licensing of other technologies
for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical
operation, Suzhou Erye, manufactures and distributes generic antibiotics in
China. For more information, please visit: http://www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward looking
statements include statements herein with respect to the successful
execution of the Company's strategy, including the final receipt of the
award described herein, as well as other advances in the Company's business,
about which no assurances can be given. The Company's actual results could
differ materially from those anticipated in these forward-looking statements
as a result of various factors. Factors that could cause future results to
materially differ from the recent results or those projected in forward-
looking statements include the "Risk Factors" described in the Company's
Annual Report on Form 10-K filed with the Securities and Exchange Commission
on March 31, 2010 as well as other periodic filings made with the
Securities and Exchange Commission. The Company's further development is
highly dependent on future medical and research developments and market
acceptance, which is outside its control.
For more information, please contact:
NeoStem, Inc.
Robin Smith, CEO
Phone: +1-212-584-4174
Email: r****[email protected]
Web: http://www.neostem.com
SOURCE NeoStem, Inc.
Wednesday
CEO,
15
【在 f**********g 的大作中提到】
: Anyone familiar with NBS?
: http://finviz.com/screener.ashx?v=341&t=NBS
: NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday
: , January 12, 2011
: 1 hours 20 minutes ago - PRN
: PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
: international biopharmaceutical company with operations in the U.S. and
: China, today announced that Dr. Robin Smith, the Company's Chairman and CEO,
: will present on Wednesday, January 12, 2011 at the OneMedForum 2011 at 9:15
: AM PST and at the Biotech Showcase(TM) 2011 at 11:00 AM PST. Both events
| q********g
发帖数: 10694 | | | | g*********1
发帖数: 725 | 11 I don't know NBS, but its chart looks good to me. I already bought in
yesterday.
【在 f**********g 的大作中提到】
: $1,700,000 Funding of NeoStem's Very Small Embryonic-Like Stem Cells Being
: Developed to Treat Osteoporosis Recommended by the Department of Defense
: Peer Reviewed Medical Research Program
: 41 minutes ago - PRN
: PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
: international biopharmaceutical company with operations in the U.S. and
: China, today announced that its FY2010 Technology/Therapeutic Development
: Award application number PR101055 has been recommended for funding by the
: Department of Defense (DOD) Peer Reviewed Medical Research Program (PRMRP)
: of the Office of the Congressionally Directed Medical Research Programs (
| f**********g
发帖数: 2252 | 12 me 2, bot just for TA. Vol is low though.
【在 g*********1 的大作中提到】
: I don't know NBS, but its chart looks good to me. I already bought in
: yesterday.
| y*****l
发帖数: 5997 | | q********g
发帖数: 10694 | 14 好~~顶
手里捂着AVII均价1.85。NBS看起来挺适合我的风格的。 | f**********g
发帖数: 2252 | 15 NBS CUR chart looks good, but do not know their drugs.
【在 q********g 的大作中提到】
: 好~~顶
: 手里捂着AVII均价1.85。NBS看起来挺适合我的风格的。
| f**********g
发帖数: 2252 | | q********g
发帖数: 10694 | 17 这个太猛了~~
【在 f**********g 的大作中提到】
: PSTI continue up.
| i****s
发帖数: 1152 | 18 这avii看的我胆战心惊的。今天一大叉，在加上KDJ和RSI都说是超买了....
本来还指望3呢.... | f**********g
发帖数: 2252 | 19 ASTM continue after pullback.
PSTI continue up.
AVII pullback. | f**********g
发帖数: 2252 | 20 Anyone familiar with NBS?
http://finviz.com/screener.ashx?v=341&t=NBS
NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday
, January 12, 2011
1 hours 20 minutes ago - PRN
PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
international biopharmaceutical company with operations in the U.S. and
China, today announced that Dr. Robin Smith, the Company's Chairman and CEO,
will present on Wednesday, January 12, 2011 at the OneMedForum 2011 at 9:15
AM PST and at the Biotech Showcase(TM) 2011 at 11:00 AM PST. Both events
will be held in San Francisco, California.
The OneMedForum 2011 will be held at the Sir Francis Drake Hotel at 450
Powell Street, San Francisco, CA and Dr. Robin Smith will present in the
Renaissance Room. The Biotech Showcase(TM) 2011 will be held at Parc 55
Wyndham San Francisco, CA and Dr. Robin Smith will present in the Stockton
Room.
In recapping highlights of 2010, the Company will review its multiple
accomplishments for the year. In November 2010, we raised $19 million from
two concurrent offerings. These funds will help us to grow our revenue lines
of businesses in the US and China, including the closing of our acquisition
of Progenitor Cell Therapy LLC, and further assist in our growth. NeoStem
was also named "Best Stem Cell Company, 2010" in The New Economy's Biotech
Awards. Additionally, The Vatican's Pontifical Council has undertaken to
commit $1 million to joint ventures with NeoStem and the Stem for Life
Foundation, a not-for-profit entity NeoStem participated in founding, to
expand research and raise awareness of adult stem cell therapies.
We also began generating revenues from what we believe will be just the
beginning of a pipeline of stem cell-based regenerative medicine therapies,
a key element of our growth strategy in both the United States and China,
with our collaboration with Wendeng Hospital in China whereby patients are
being offered the benefit of the latest technology from the US in the
treatment of a range of orthopedic conditions. Additionally, the ongoing
relocation to Suzhou Erye Pharmaceutical's new manufacturing facility
continues to progress and should be completed in 2011 thereby significantly
increasing capacity.
"I look forward to the opportunity to detail some of these exciting
developments as well as discuss some of our upcoming milestones at these two
industry events in San Francisco," said Dr. Robin Smith.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies,
pursuit of anti-aging initiatives and building of a network of adult stem
cell collection centers in the U.S. and China that are focused on enabling
people to donate and store their own (autologous) stem cells for their
personal use in times of future medical need. The Company also has licensed
various stem cell technologies, including a worldwide exclusive license to
VSEL(TM) Technology which uses very small embryonic-like stem cells, shown
to have several physical characteristics that are generally found in
embryonic stem cells, and is pursuing the licensing of other technologies
for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical
operation, Suzhou Erye, manufactures and distributes generic antibiotics in
China. For more information, please visit: http://www.neostem.com.
About the Biotech Showcase(TM) (Innovation - Opportunity - Collaboration)
Now in its third year, Biotech Showcase(TM) will feature corporate
presentations by 195 innovative life science companies to an audience of
public and private investors, business development executives and
professional advisors who are interested in investment opportunities and
collaboration. The showcase takes place during the week of one of the most
important healthcare investor conferences which annually attracts thousands
of healthcare and life science business executives to San Francisco in a
venue located close to the center of action. More can be found on their
website: http://www.ebdgroup.com/bts/index.php.
【在 f**********g 的大作中提到】
: NBS CUR chart looks good, but do not know their drugs.
| | | f**********g
发帖数: 2252 | 21 $1,700,000 Funding of NeoStem's Very Small Embryonic-Like Stem Cells Being
Developed to Treat Osteoporosis Recommended by the Department of Defense
Peer Reviewed Medical Research Program
41 minutes ago - PRN
PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
international biopharmaceutical company with operations in the U.S. and
China, today announced that its FY2010 Technology/Therapeutic Development
Award application number PR101055 has been recommended for funding by the
Department of Defense (DOD) Peer Reviewed Medical Research Program (PRMRP)
of the Office of the Congressionally Directed Medical Research Programs (
CDMRP).
The $1,700,000 award, which the Company will receive upon completion of the
award process, will be applied towards funding the Company's proposal to
continue a strategy aimed at employing the Company's VSEL(TM) Technology
which uses a unique stem cell population, very small embryonic-like stem
cells, to treat osteoporosis and improve bone health.
"The work proposed in this application has the potential to dramatically
change the way in which osteoporosis and bone fracture is treated in the
military and in the general population," said Dr. Russell Taichman,
Professor of Dentistry, Department of Periodontics and Oral Medicine at the
University of Michigan's School of Dentistry who will work with the Company
on the study. Dr. Taichman added "Osteoporosis is a major medical condition
affecting 75 million people worldwide and causing significant morbidity and
mortality in the aging population and the increased incidence of fractures
is the major cause of death from osteoporosis. In 2005, the estimated cost
burden of fractures due to osteoporosis was $19 billion and that is expected
to rise to over $25 billion by the year 2025. In addition to being a major
concern for the general healthcare community, osteoporosis and related bone
fractures have become a concern for the military with significant loss of
duty time across all branches of the military due to related stress
fractures."
Dr. Denis Rodgerson, NeoStem's Director of Stem Cell Science and Principal
Investigator for the study commented, "We are honored to have been
recommended for this award. It will enable us, together with Dr. Taichman as
co-Principal Investigator and his colleague Dr. Laurie K. McCauley, Chair,
Department of Periodontics and Oral Medicine at the University of Michigan's
School of Dentistry and Professor of Pathology at the University of
Michigan Medical School, to explore the significant potential for VSEL(TM)
Technology to provide benefits in autologous, cell-based therapies for
osteoporosis and other diseases of the bone."
Dr. Robin Smith, NeoStem's CEO commented, "We are thrilled that such a
preeminent authority as the Department of Defense shares our excitement and
vision regarding the clinical applications of our licensed technologies and
continues to support the advancement of our VSEL(TM) Technology in multiple
clinical applications."
NeoStem has a worldwide exclusive license to VSEL(TM) Technology which uses
very small embryonic-like stem cells, a heterogeneous population of stem
cells found in adult bone marrow that have properties similar to those of
embryonic stem cells. NeoStem has shown that very small embryonic-like stem
cells can be mobilized into the peripheral blood, enabling a minimally
invasive means for collecting what NeoStem believes to be an important
population of stem cells that may have the potential to achieve the positive
benefits associated with embryonic stem cells without the ethical or moral
dilemmas or the potential negative effects associated with embryonic stem
cells.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies,
pursuit of anti-aging initiatives and building of a network of adult stem
cell collection centers in the U.S. and China that are focused on enabling
people to donate and store their own (autologous) stem cells for their
personal use in times of future medical need. The Company also has licensed
various stem cell technologies, including a worldwide exclusive license to
VSEL(TM) Technology which uses very small embryonic-like stem cells, shown
to have several physical characteristics that are generally found in
embryonic stem cells, and is pursuing the licensing of other technologies
for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical
operation, Suzhou Erye, manufactures and distributes generic antibiotics in
China. For more information, please visit: http://www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward looking
statements include statements herein with respect to the successful
execution of the Company's strategy, including the final receipt of the
award described herein, as well as other advances in the Company's business,
about which no assurances can be given. The Company's actual results could
differ materially from those anticipated in these forward-looking statements
as a result of various factors. Factors that could cause future results to
materially differ from the recent results or those projected in forward-
looking statements include the "Risk Factors" described in the Company's
Annual Report on Form 10-K filed with the Securities and Exchange Commission
on March 31, 2010 as well as other periodic filings made with the
Securities and Exchange Commission. The Company's further development is
highly dependent on future medical and research developments and market
acceptance, which is outside its control.
For more information, please contact:
NeoStem, Inc.
Robin Smith, CEO
Phone: +1-212-584-4174
Email: r****[email protected]
Web: http://www.neostem.com
SOURCE NeoStem, Inc.
Wednesday
CEO,
15
【在 f**********g 的大作中提到】
: Anyone familiar with NBS?
: http://finviz.com/screener.ashx?v=341&t=NBS
: NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday
: , January 12, 2011
: 1 hours 20 minutes ago - PRN
: PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
: international biopharmaceutical company with operations in the U.S. and
: China, today announced that Dr. Robin Smith, the Company's Chairman and CEO,
: will present on Wednesday, January 12, 2011 at the OneMedForum 2011 at 9:15
: AM PST and at the Biotech Showcase(TM) 2011 at 11:00 AM PST. Both events
| q********g
发帖数: 10694 | | g*********1
发帖数: 725 | 23 I don't know NBS, but its chart looks good to me. I already bought in
yesterday.
【在 f**********g 的大作中提到】
: $1,700,000 Funding of NeoStem's Very Small Embryonic-Like Stem Cells Being
: Developed to Treat Osteoporosis Recommended by the Department of Defense
: Peer Reviewed Medical Research Program
: 41 minutes ago - PRN
: PR NewswireNeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
: international biopharmaceutical company with operations in the U.S. and
: China, today announced that its FY2010 Technology/Therapeutic Development
: Award application number PR101055 has been recommended for funding by the
: Department of Defense (DOD) Peer Reviewed Medical Research Program (PRMRP)
: of the Office of the Congressionally Directed Medical Research Programs (
| f**********g
发帖数: 2252 | 24 me 2, bot just for TA. Vol is low though.
【在 g*********1 的大作中提到】
: I don't know NBS, but its chart looks good to me. I already bought in
: yesterday.
|
|
